- Home
- TNDM
as 07-26-2024 4:00pm EST
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Upcoming Earnings Alert:
Get ready for potential market movements as Tandem Diabetes Care Inc. TNDM prepares to release earnings report on 01 Aug 2024.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | San Diego |
| Market Cap: | 3.0B | IPO Year: | 2013 |
| Target Price: | $49.92 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.82 - $53.69 | Next Earning Date: | 08-01-2024 |
| Revenue: | $770,009,000 | Revenue Growth: | -3.11% |
| Revenue Growth (this year): | 18.66% | Revenue Growth (next year): | 11.56% |
Stock Insider Trading Activity of Tandem Diabetes Care Inc. (TNDM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Allen Dick | TNDM | Director | May 30 '24 | Sell | $51.68 | 5,000 | $258,400.00 | 0 | SEC Form 4 |
| Allen Dick | TNDM | Director | Nov 27 '23 | Buy | $18.96 | 5,000 | $94,777.50 | 19,962 | SEC Form 4 |
| Hansen Shannon Marie | TNDM | Chief Legal Officer | Nov 8 '23 | Buy | $15.44 | 1,935 | $29,884.33 | 1,935 | SEC Form 4 |
Latest Tandem Diabetes Care Inc. News
TNDM Breaking Stock News: Dive into TNDM Ticker-Specific Updates for Smart Investing
The Wall Street Journal
10 hours ago
Are Ozempic Jitters to Blame for DexCom's Stock-Price Plunge?
Morningstar Research
a day ago
Analyst Report: Tandem Diabetes Care, Inc.
Argus Research
3 days ago
TNDM: Lowering target price to $46.00
Argus Research
10 days ago
TNDM: Raising target price to $49.00
Business Wire
15 days ago
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
Morningstar Research
16 days ago
Analyst Report: Tandem Diabetes Care, Inc.
Argus Research
17 days ago
TNDM: Raising target price to $45.00
Zacks
25 days ago
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
Compare TNDM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNDM Tandem Diabetes Care Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.